Exenatide

Generic Name: Exenatide

Brand Names: Bydureon, Byetta

Drug Type: Biotech

CAS Number: 141758-74-9

Unique Ingredient Identifier: 9P1872D4OL

Background: Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations. Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.

Indication: Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old, while the immediate-acting formulation is approved only for adult patients.

Associated Conditions: Type 2 Diabetes Mellitus

Clinical Trials

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Recruiting

Conditions: Type 2 Diabetes Mellitus
Cardiovascular Diseases

First Posted Date: 2021-10-11

Last Posted Date: 2024-10-24

Lead Sponsor: Kaiser Permanente

Target Recruit Count: 270000

Registration Number: NCT05073692

Locations: 🇺🇸
Romain S. Neugebauer, Oakland, California, United States
🇺🇸
Kaiser Permanente Southern California, Pasadena, California, United States
🇺🇸
Kaiser Permanente Hawaii, Honolulu, Hawaii, United States

and more 3 locations

Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.

Phase 4

Completed

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Metformin
Drug: Exenatide

First Posted Date: 2021-07-21

Last Posted Date: 2022-04-14

Lead Sponsor: Bing He

Target Recruit Count: 60

Registration Number: NCT04969627

Locations: 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

Exenatide for Treating Cocaine Use Disorder

Phase 1

Completed

Conditions: Cocaine Use Disorder

Interventions: Drug: Exenatide 2 mg [Bydureon]
Behavioral: Drug Counseling

First Posted Date: 2021-06-28

Last Posted Date: 2022-06-27

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 3

Registration Number: NCT04941521

Locations: 🇺🇸
UTHealth Behavioral and Biomedical Sciences Building, Houston, Texas, United States

Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia

Not Applicable

Completed

Conditions: Endogenous Hyperinsulinism

Interventions: Drug: Exenatide
Drug: 0.9% saline solution

First Posted Date: 2021-06-01

Last Posted Date: 2024-05-08

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 29

Registration Number: NCT04909333

Locations: 🇨🇭
University Hospital Basel, Division of Nuclear Medicine, Basel, Switzerland

Brain Activation and Satiety in Children 2

Phase 3

Active, not recruiting

Conditions: Childhood Obesity

Interventions: Behavioral: Family Based Behavioral Treatment
Drug: Exenatide 2 mg [Bydureon]
Drug: Placebo

First Posted Date: 2020-08-20

Last Posted Date: 2025-05-15

Lead Sponsor: Seattle Children's Hospital

Target Recruit Count: 63

Registration Number: NCT04520490

Locations: 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States

Exenatide Once-weekly as a Treatment for Multiple System Atrophy

Phase 2

Conditions: Multiple System Atrophy

Interventions: Drug: Exenatide Pen Injector [Bydureon]

First Posted Date: 2020-06-16

Last Posted Date: 2020-11-05

Lead Sponsor: University College, London

Target Recruit Count: 50

Registration Number: NCT04431713

Locations: 🇬🇧
Leonard Wolfson Experimental Neurology Centre, National Hospital of Neurology and Neurosurgery, UCLH NHS Foundation trust, London, United Kingdom